Abstract: The present invention is directed to compounds, intermediates and methods for making valerenic acid and its derivatives as well as the use of such compounds as GABAA receptor ligands.

Abstract: The present invention is directed to compounds, intermediates and methods for making valerenic acid and its derivatives as well as the use of such compounds as GABAA receptor ligands.

Abstract: The present invention is directed to compounds, intermediates and methods for making valerenic acid and its derivatives as well as the use of such compounds as GABAA receptor ligands.

Abstract: This invention relates to a process for the production of epothilone B and derivatives as well as intermediate products for this process. In the new process, epothilone B or the derivatives are built up in high yields from the C1-C6, C7-C10 and C11-C20 fragments (2, 3 and 4) that can be obtained at a reasonable price and free of diastereomers (the variable radicals have the meanings that are indicated in the description).

Abstract: The invention relates to a method for producing epothilone B and derivatives, and to intermediate products for this method. According to the novel method, the epothilone B or derivatives are produced in high yields from the C1-C6, C7-C10 and C11-C20-fragments 2, 3 and 4 that can be obtained economically and diastereomerically purely (the variable radicals having the meanings given in the description ).

Abstract: Thiazole derivatives of formula II, in which R1 means C1-C4 alkyl, R2 means any protective group that can be chelated, R3 means hydrogen or C1-C4 alkyl, Y means CO2R4, CHO, CH—CH2 or CH2R5, whereby R4 stands for C1-C4 alkyl and an optionally substituted benzyl group, R5 stands for halogen, hydroxy, p-toluenesulfonate and —OSO2B and B stands for C1-C4 alkyl or C1-C4 perfluoroalkyl, can be produced free of diastereomers and are suitable for the production of epothilone A and epothilone B and derivatives thereof.

Abstract: The invention concerns LHRH antagonists of the general formula (I),X-X.sub.1 -X.sub.2 -X.sub.3 -L-Ser-L-Tyr-X.sub.6 -L-Leu-X.sub.8 -L-Pro-X.sub.10 (I)The invention concerns LHRH antagonists of the general formula (I), in which X is an acyl group, X.sub.1 is a D-Nal, X.sub.2 is D-(4-Cl)-Phe, X.sub.3 is D-(3)-Pal, X.sub.6 is D-Cit or D-Neu, X.sub.8 is L-Arg or L-Neu, at least one of the groups X.sub.6 and X.sub.8 being a Neu, and X.sub.10 is D-Ala-NH.sub.2, Neu being a group of formula (II), (IV), (IX) or (X), wherein W is one of the group (a)-(d). The invention includes drugs containing a compound of formula (I), plus the usual auxiliaries and carriers. These drugs are suitable for use in cases of carcinoma of the prostate and in endometriosis, as well as for fertility control.